39 results about "Hemophilus parasuis" patented technology

The invention relates to the field of preparation of animal husbandry vaccines, in particular to a porcine circovirus, mycoplasma hyopneumoniae and haemophilus parasuis triple vaccine which comprises 30-50 parts of first bacterial liquid containing inactivated haemophilus parasuis; an adjuvant; 40 to 60 parts of a culture solution of a mycoplasma hyopneumoniae culture; 30-40 parts of a second bacterial liquid containing inactivated porcine circovirus; 1 to 10 parts of tween-80; 2-6 parts of aluminum stearate; 1 to 3 parts of interleukin; and 2-4 parts of squalane. The vaccine is mainly applied to prevention of porcine circovirus, mycoplasma hyopneumoniae and haemophilus parasuis for boars and piglets in a pig farm, reduces the multi-system failure syndrome, mycoplasma hyopneumoniae, polyserositis, arthritis and meningitis of weaned piglets in the pig farm and the morbidity of multi-infection-source successive infection, and improves the survival efficiency of the piglets.

The invention belongs to the technical field of biology, and discloses a construction method of a swine cholera attenuated salmonella recombinant strain capable of simultaneously expressing a haemophilus parasuis outer membrane protein GAPDH gene and an Omp26 gene, a plasmid connected with the haemophilus parasuis GAPDH gene and the Omp26 gene is adopted to transfect a swine cholera salmonella asd gene deleted strain, screening is carried out, and screening is carried out to obtain the swine cholera attenuated salmonella recombinant strain capable of simultaneously expressing the haemophilus parasuis outer membrane protein GAPDH gene and the Omp26 gene. The recombinant attenuated salmonella choleraesuis expressing the haemophilus parasuis GAPDH gene and the Omp26 gene is obtained. The strain can simultaneously express a haemophilus parasuis outer membrane protein GAPDH gene and an Omp26 gene, and compared with a strain which singly expresses Omp26, the strain has the advantage that the immune protection effect is obviously improved. Meanwhile, the invention also provides a construction method and application of the strain.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

The invention discloses a haemophilus parasuis high-density fermentation culture medium as well as a culture method and application thereof, and relates to the technical field of microbial fermentation. The haemophilus parasuis high-density fermentation culture medium is prepared from the following components according to the content in 1L: 1.8 to 2g / L of glucose, 20 to 25g / L of organic nitrogen source, 2.0 to 3.0 g / L of dipotassium phosphate, 4.5 to 5.5 g / L of sodium chloride, 0.5 to 1.8 mg / L of NAD (Nicotinamide Adenine Dinucleotide), 8.2 to 8.6 mL / L of fetal calf serum and the balance of water, and the pH value is 7.0 to 7.5; wherein the organic nitrogen source is composed of Oxoid yeast and green source soybean peptone in a mass ratio of 1: 2. By optimizing the proportion of the glucose, the organic nitrogen source and the fetal calf serum, the viable count of the haemophilus parasuis is remarkably increased, when the culture medium is used for fermentation culture, OD600 can reach 1.8 through 7-hour fermentation, the viable count reaches 1010 CFU / mL, the viable count is increased by more than one time compared with that of a traditional culture medium, and the culture medium is suitable for large-scale production. And a high-density thallus raw material is provided for vaccine production.

The invention discloses a bivalent subunit vaccine for preventing infection of haemophilus parasuis and porcine circovirus type 2. A core antigen combination of the vaccine comprises at least one antigen protein from haemophilus parasuis, and the antigen protein is selected from Ferrin, OppA and Hem-SAP and is combined with a porcine circovirus type 2 Cap protein. Wherein the NCBI (National Center of Biotechnology Information) login number of the Ferrin, the NCBI login number of the OppA and the NCBI login number of the Hem-SAP are WP160414389.1, ACL32731.1 and WP035493594.1 respectively. The antigen protein is subjected to codon optimization, is expressed and purified through a prokaryotic expression system, and is emulsified with ISA201 or a Freund's adjuvant to prepare the vaccine. Animal experiments prove that the vaccine can excite high-level antigen specificity IgG, cell factors IFN-gamma and white IL-4 in an immune animal body, namely, specific Th1 and Th2 type immune responses are generated. The vaccine can generate an immune protection rate of up to 80% when attacked by a serum type 5 haemophilus parasuis virulent strain, and generates an effective antibody response to the porcine circovirus type 2. The vaccine provided by the invention has the advantages of definite components, good safety and strong immune protection force.

The invention discloses an application of an ST6GALNAC5 gene in prevention and treatment of swine Graisseria disease (a pathogenic bacterium causing the swine Graisseria disease by a haemophilus parasuis system), and the expression of the ST6GALNAC5 gene is inhibited in a targeted manner, so that adhesion and invasion of the haemophilus parasuis to host cells can be effectively inhibited, and cytopathy is reduced. The method is helpful for resisting cell death induced by haemophilus parasuis infection, so as to prevent the occurrence of the porcine Graisseria disease. Therefore, the ST6GALNAC5 gene can be used as an important target spot for treating the swine Graisseria disease, and has important clinical application prospects and molecular disease-resistant breeding values.

The invention belongs to the technical field of biology, and relates to a narrow-spectrum antibacterial peptide XMK-8 and application thereof. The amino acid sequence of the narrow-spectrum antibacterial peptide XMK-8 is as shown in SEQ ID NO: 1, and the narrow-spectrum antibacterial peptide XMK-8 has no bacteriostatic activity on escherichia coli, salmonella, staphylococcus aureus and aeromonas hydrophila and only has bacteriostatic activity on pasteurella multocida and haemophilus parasuis. The antibacterial activity of the narrow-spectrum antibacterial peptide XMK-8 can still be detected after treatment with salt ions (sodium ions and potassium ions, 50-200 mmol / L), acid-base (pH 4-10) and protease K (20-100 [mu] g / mL) at the temperature of 0-100 DEG C, and the narrow-spectrum antibacterial peptide XMK-8 has low hemolytic activity on red blood cells of mice. The antibacterial peptide XMK-8 disclosed by the invention is expected to become a novel antibiotic substitute and has a good application prospect in prevention, treatment, diagnosis and identification of pasteurella multocida, haemophilus parasuis and infection thereof.

The present invention is applicable to the technical field of veterinary vaccines, and provides a subunit antigen Ptsg, an antigen combination, a subunit vaccine and an application thereof for Haemophilus parasuis immune protection. The amino acid sequences of the antigens Ptsg, Vacj, GAPDH and PalA are shown in SEQ ID NO.1 to SEQ ID NO.4, respectively, and the nucleotide sequences encoding the antigens Ptsg, Vacj, GAPDH and PalA are shown in SEQ ID NO.5 to SEQ ID NO.8, respectively. The subunit vaccine comprises an antigen combination and an adjuvant MontanideTM Gel 01. The subunit vaccine can be used in the preparation of drugs for preventing and treating Haemophilus parasuis. The present invention lays a foundation for the development of an efficient, low-cost and broad-spectrum subunit vaccine for Haemophilus parasuis, provides an effective technical means for the prevention and treatment of the disease, and has important application value and promotion prospects.

The present invention refers to the veterinary field. Particularly, it refers to a strain of Glaesserella parasuis, or a composition comprising thereof. Preferably, the strain or composition is for use in a method for the prevention and / or treatment of Glässer's disease or a condition caused by infection with a virulent Glaesserella parasuis strain. It also refers to a device suitable for administering a medicine to porcine animals characterized in that it comprises a non-virulent live strain of Glaesserella parasuis.

The invention relates to the technical field of gene engineering, and particularly discloses a serum type 5 haemophilus parasuis attenuated vaccine strain without antibody polygene deletion as well as a construction method and application of the serum type 5 haemophilus parasuis attenuated vaccine strain. According to the invention, crp, cpxAR and OmpP2 genes related to toxicity are deleted from a clinical isolated strain of a haemophilus parasuis serum type 5 virulent strain HN1570 by means of molecular biology to obtain a non-resistant polygene deleted strain HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR, and the deleted strain is preserved; tests find that the attenuated live vaccine prepared by using the HPS5deltaOmpP2 deltacrp deltacpxAR strain haemophilus parasuis as a strain antigen not only has 100% protection rate on infection of type 5, but also has better cross protection force on infection of other serotype haemophilus parasuis and haemophilus parasuis incapable of being classified, and a good immune protection effect can be achieved by using a small immunization amount; the result shows that the haemophilus parasuis HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR strain has good immunogenicity; the vaccine is simple in preparation process, free of resistance genes, free of toxic and side effects, good in safety, long in immune period and good in immune effect, and can be used for industrial production.

The present invention relates to a marker for detecting the skeletal muscle atrophy of pigs infected with Haemophilus parasuis, wherein the marker at least includes FOXO1, FBXO32, TRIM63, CTSL and BNIP3; when the expression levels of FOXO1, FBXO32, TRIM63, CTSL and BNIP3 are higher than the average expression levels of healthy individuals, muscle fiber atrophy occurs in pork. The present invention compares the expression levels of the markers of individuals infected with Haemophilus parasuis with the average expression levels of healthy individuals; according to the comparison results, the skeletal muscle atrophy of the individuals infected with Haemophilus parasuis is determined, and then the meat production trait is determined according to the skeletal muscle atrophy, and the method can also be used to screen out individuals with non-atrophic skeletal muscles for breeding.

The invention discloses a heat-resistant protective agent live vaccine for highly pathogenic porcine reproductive and respiratory syndrome, and belongs to the technical field of protective agent vaccines.The heat-resistant protective agent live vaccine is prepared by the following steps: S1, cell culture: carrying out bioreactor cell microcarrier suspension culture according to a monkey embryo kidney epithelial cell Marc-145 microcarrier cell suspension culture process; according to the preparation method, the first antigen liquid and the second antigen liquid are extracted and mixed, the pig alpha interferon is added to be matched with the aluminum hydroxide adjuvant to obtain the composite immunologic adjuvant, and the antigen vaccine is prepared by adopting a suspension culture process; the vaccine can effectively improve the virus titer, achieves the effect of simultaneously preventing the high-pathogenicity porcine reproductive and respiratory syndrome virus and the haemophilus parasuis disease, avoids the condition of mixed infection, and greatly improves the immune regulation effect of the vaccine and enhances the vaccine effect by virtue of the composite immunologic adjuvant.

The invention discloses serum for fermentation of haemophilus parasuis as well as a preparation method and application thereof, and belongs to the technical field of animal vaccine production. The customized serum comprises the following components: newborn calf serum, sodium glutamate, a plant extract, NAD (Nicotinamide Adenine Dinucleotide), MgSO4, glycerol and glycine. All components of the customized serum do not contain porcine exogenous viruses, and the customized serum is matched with a TSB culture medium for use, so that the fermentation time of haemophilus parasuis is shortened, and the antigen density is improved. According to the method disclosed by the invention, the safety is ensured, the problems that the traditional haemophilus parasuis fermentation only uses TSB, NAD and serum, the time is long, and the antigen density is low are solved, and all components needing to be additionally added are added into the customized serum, so that the culture medium preparation process before fermentation is simplified.

The invention relates to the technical field of biology, and particularly discloses haemophilus parasuis and preparation and application of an egg yolk antibody of the haemophilus parasuis. The invention relates to haemophilus parasuis, which is preserved in the China General Microbiological Culture Collection Center, and is named as haemophilus parasuis HPS22001, the preservation date is December 24, 2024, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.46273. The haemophilus parasuis HPS22001 is named as haemophilus parasuis HPS22001. The HPS-LPS polysaccharide antigen prepared from the haemophilus parasuis HPS22001 and an egg yolk antibody prepared by using the HPS inactivated vaccine as immunogens can be used for effectively preventing and treating haemophilus parasuis diseases.

The invention relates to the field of biological medicine, in particular to an anti-haemophilus parasuis composition and application thereof.The composition adopts 3-hydroxyflavone as an active ingredient for resisting haemophilus parasuis and can show a very good sterilization effect; meanwhile, the invention further discloses application and a medicine of the composition.

The invention belongs to the technical field of biology, relates to a haemophilus parasuis subunit vaccine as well as a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises a recombinant P3 protein and a recombinant P5 protein, the recombinant P3 protein is coded by a sequence shown in SEQ ID No.1, the recombinant P5 protein is coded by a sequence shown in SEQ ID No.2, and the recombinant P3 protein is coded by a sequence shown in SEQ ID No.2. The vaccine immunization can induce effective respiratory mucosa immune response, meanwhile, humoral immune and cellular immune response are remarkably induced, the safety is high, live pathogens are not involved in the vaccine preparation process, no adverse reaction is generated after immunization, and mucosa immunity can be activated when the vaccine immunizes a body; the required antigen content is obviously lower than that of the existing vaccine, the mucosal immunity is enhanced and the immune duration is prolonged by screening adjuvants, and a good immune protection effect can be provided.

The invention belongs to the technical field of biology, particularly relates to a haemophilus parasuis disease mucosal immune vaccine, a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises one or more of a recombinant P2 protein, a recombinant P3 protein and a recombinant P6 protein, sequences for coding the haemophilus parasuis antigen combination are shown as SEQ ID No.1-3 respectively, and the haemophilus parasuis antigen combination comprises one or more of the recombinant P2 protein, the recombinant P3 protein and the recombinant P6 protein. The haemophilus parasuis antigen combination is prepared into a haemophilus parasuis disease mucosal immune vaccine, the haemophilus parasuis disease mucosal immune vaccine is safe and free of biological safety risks, an immune body can activate comprehensive immune reactions including humoral immunity and cellular immunity, and more importantly, remarkable mucosal immunity can be induced; the antigen has good immunogenicity and good conservative property, and can provide broader spectrum protection. By means of mucous membrane immunization, conventional injection immune stress reaction is reduced, and side reaction is small. And the problem that pathogenic bacteria are not thoroughly inactivated possibly in the production of the inactivated vaccine is also solved, the pathogenic bacteria diffusion and pollution risks are reduced, and the method has a wide application prospect.

The present invention belongs to the technical field of pathogenic bacterial disease prevention and treatment, and specifically relates to a fusion antigen of the N-terminus of IRP protein of Haemophilus parasuis and RLPB protein and its application. The amino acid sequence of the fusion antigen is shown in SEQ ID NO: 1. The reactivity of the fusion antigen is identified by Western-Blot, and it can be known that the fusion protein antigen can be recognized by the positive serum of Haemophilus parasuis antibody; and the indirect ELISA method constructed based on the fusion antigen has excellent specificity, sensitivity and repeatability for the positive serum of Haemophilus parasuis antibody; in addition, immunizing guinea pigs with the fusion antigen can obtain the protection effect against the attack of Haemophilus parasuis type 1 strain, type 5 strain and type 13 strain.

The invention discloses a continuous fermentation device for haemophilus parasuis and a culture process. The fermentation device comprises a fermentation treatment assembly, the fermentation treatment assembly comprises a vertical pipe which penetrates through the upper cover and is rotationally connected with the upper cover, the driving mechanism drives the vertical pipe to rotate so as to drive a rectangular cylinder, a rectangular piston, a short pipe, a reciprocating screw rod, a connecting pipe and an arc-shaped pipe to rotate, meanwhile, the arc-shaped pipe is gradually and horizontally arranged, and negative pressure is generated at a defoaming hole; fermentation bubbles generated by fermentation can be removed from the middle to the inner wall of the fermentation cylinder, and fermentation liquid can be mixed; the culture process comprises the following steps: S1, inoculating a culture medium with a haemophilus parasuis strain, and culturing for 28-32 hours in a CO2 constant-temperature incubator with the culture temperature of 37 DEG C and the volume fraction of 3%. According to the device, fermentation liquor and a fermentation culture medium can be fully mixed, meanwhile, effective and efficient defoaming treatment can be conducted on fermentation bubbles in a targeted mode, and the fermentation efficiency is improved.

The invention discloses a method for establishing a model for inflammation of mouse brain microvascular endothelial cells infected by haemophilus parasuis, which is used for simulating the process of porcine meningitis caused by haemophilus parasuis infection by using the mouse brain microvascular endothelial cells infected by haemophilus parasuis and researching the pathogenesis of the porcine meningitis caused by haemophilus parasuis. The optimal MOI of mouse brain microvascular endothelial cells infected by haemophilus parasuis is 1, the optimal infection time is 6 h, under the condition, the inflammatory factor level of the cells is remarkably increased, and the success rate of the cell inflammation model construction method is higher.

The invention discloses a response surface optimization haemophilus parasuis fermentation method, through a single factor experiment and a Box-Behnken response surface optimization test, by taking the maximum viable count of haemophilus parasuis 12 type as an evaluation index, the optimized haemophilus parasuis 12 type fermentation medium comprises the following components: yeast extract = 0.5919998%, NAD = 0.0952694%, magnesium sulfate = 0.211466 g / L, and bovine serum concentration = 9.91374%. The haemophilus parasuis used in the invention is a rare pathogenic bacterium and belongs to a gram-negative bacterium. The strain mainly infects pigs, causes serious respiratory system diseases and seriously affects stable development of the pig breeding industry; the HPS fermentation process is optimized and researched, so that the yield of the haemophilus parasuis is increased, and meanwhile, the application value and the economic benefit of the haemophilus parasuis as a vaccine product subsequently can be increased.

The invention discloses actinobacillus pleuropneumoniae FJLYC01 and a bivalent inactivated vaccine prepared from the actinobacillus pleuropneumoniae FJLYC01, and relates to the technical field of microorganisms and immunity. The collection number of the actinobacillus pleuropneumoniae FJLYC01 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.30270, and the actinobacillus pleuropneumoniae FJLYC01 is serum type 1 and is high in immunogenicity and good in immune effect. A bivalent vaccine prepared from the strain and haemophilus parasuis serum type 4 and type 5 strains has a very good immune protection effect on single or mixed infection of haemophilus parasuis and actinobacillus pleuropneumoniae, is safe and free of side effects, and reduces the number of immunization times and the stress of pigs compared with single-linked immunization; and the immune cost is reduced. The multi-prevention effect is achieved by one injection clinically, the hidden danger of poison dispersing does not exist, and safety and reliability are achieved.

The invention belongs to the technical field of vaccine preparation, and particularly relates to a haemophilus parasuis adjuvant vaccine which comprises the following ingredients: serum type 4 haemophilus parasuis liquid, serum type 5 haemophilus parasuis liquid, an alumina gel adjuvant, a composite polysaccharide immunopotentiator, methanol, a solid culture medium and a liquid culture medium. According to the invention, the vaccine stock solution prepared by adding the mixed adjuvant and mixing serum type 4 and type 5 haemophilus parasuis solutions is inactivated and then inoculated to piglets, so that a larger antigen library is formed in the bodies of the piglets, the antigen library is slowly released in the application process, the action time of the antigen is prolonged, and meanwhile, the vaccine has a better promotion effect on the immune effect; the inoculation frequency is reduced, the drug resistance can be alleviated, the cost expenditure of farmers is reduced, and the morbidity and mortality of swinery are reduced.

The invention discloses a lateral chromatography test strip for synchronously detecting haemophilus parasuis and actinobacillus pleuropneumoniae based on dual signal amplification and application of the lateral chromatography test strip, and belongs to the technical field of biology. According to the invention, pathogen detection can be completed within 115 minutes by combining a lateral chromatography test strip detection technology of a dual signal amplification mechanism. The whole reaction is incubated under a room temperature condition, is not limited by a large expensive instrument, and is suitable for a scene in which the infection state needs to be quickly judged. Compared with the common detection technology at present, the method has the advantages that the haemophilus parasuis and the actinobacillus pleuropneumoniae in related samples of the porcine respiratory tract can be detected more sensitively, quickly and conveniently while high specificity and low detection limit are ensured, the dependence on professional technicians and laboratory precise instruments is avoided, and the method is suitable for popularization and application. The method is of great significance to rapid and accurate identification, monitoring and early prevention and treatment of porcine bacterial respiratory diseases.

The application relates to the technical field of pathogenic culture, in particular to a selective culture medium for Haemophilus parasuis and a preparation method and application thereof. The selective culture medium comprises pig lung 220-280g, glucose 1-3g, agar powder 13-17g, protein peptone 8-12g, sodium chloride 3-7g, chitosan 8-12g, calcium propionate 3-7g, green plum polysaccharide 13-17g, sodium hydroxide for adjusting the pH value to 7.8+ / -0.1, and deionized water added to 1L. Compared with the TSA+NAD culture medium commonly used for the separation of the HPS strain at present, the separation rate of the HPS is increased by 20%, the separation time is shortened by 4 times, meanwhile, the biological characteristics of the separated HPS strain are not affected, the selective culture medium can be used for the rapid separation and identification of the HPS strain, has good stability, can reduce the separation and identification cost, and improves the separation accuracy.

The present invention discloses RAB8B Application of genes in the prevention and treatment of pig Glaser's disease through targeted inhibition RAB8B Gene expression can effectively inhibit Haemophilus parasuis from adhering to and invading host cells and causing cytopathic effects, resisting cell death induced by Haemophilus parasuis infection, and thus preventing and treating swine Glasser's disease caused by Haemophilus parasuis infection. RAB8B The gene can serve as a potential target for the prevention and treatment of porcine Glasser's disease and has important clinical application value.

The invention belongs to the field of biology, and discloses a plasmid which contains a haemophilus parasuis Omp Am outer membrane protein gene and a mycoplasma hyopneumoniae membrane protein gene. The mycoplasma hyopneumoniae membrane protein gene is one or a combination of more of a mycoplasma hyopneumoniae membrane protein P46 gene, a mycoplasma hyopneumoniae membrane protein P65 gene and a mycoplasma hyopneumoniae membrane protein P159 gene. The plasmid contains an Omp Am outer membrane protein gene and a mycoplasma hyopneumoniae membrane protein gene, recombinant haemophilus parasuis is prepared from a target gene amplified from the vector through a primer in a natural transformation mode, one or more of Mhp antigen proteins such as P46 protein, P65 protein and P159 protein can be effectively expressed, and the effect of double immunization is achieved. Meanwhile, the invention also provides recombinant haemophilus parasuis and application thereof.

To provide a vaccine for protecting a pig against Haemophilus parasuis, and a method to protect a pig against Haemophilus parasuis.SOLUTION: Provided is an immunogenic composition comprising a protein having at least 69% sequence identity with the protein according to a specific sequence or an immunogenic fragment of this protein, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis. Also provided are a vaccine for protecting a pig against an infection with Haemophilus parasuis comprising the immunogenic composition and a pharmaceutically acceptable carrier, and a method to protect a pig against an infection with Haemophilus parasuis by administering the vaccine to the pig.SELECTED DRAWING: None